ECS modulator (research)
UnscheduledMK-9470
N-[(2S,3S)-3-(3-cyanophényl)-4-[4-(2-fluoroéthoxy)phényl]butan-2-yl]-2-méthyl-2-[(5-méthylpyridin-2-yl)oxy]propanamide
Aliases.[18F]MK-9470 · MK 9470
A positron emission tomography tracer of the human CB1 receptor, an inverse agonist at 0.7 nanomolar.
Updated on
Level of detail
Identifiers
- Formula
- C₂₉H₃₂FN₃O₃
- Molar mass
- 489.60 g·mol⁻¹
- CAS
- 947371-30-4
- PubChem CID
- 11488705
- Origin
- A wholly synthetic compound. Its useful form is labelled with fluorine 18, a short-lived radionuclide produced in a cyclotron, which requires preparation within the hour preceding the examination and rules out any storage. It has no natural occurrence.
- InChIKey
- XIYPJXKEMLKFMD-HFZDXXHNSA-N
In plain terms
MK-9470 serves to photograph CB1 receptors in a living brain. Labelled with a short-lived radioactive atom, it binds to those receptors and makes their distribution visible to the camera. It is an imaging tool, not a therapy.
Receptors and activity
- CB1IC50 humaine = 0,7 nM (Burns et coll. 2007)Inverse agonist
- CB2Sélectivité CB1 ; usage comme radioligand sélectifModulator
- Agonist
- Partial agonist
- Antagonist
- Modulator
- Inverse agonist
Hover over a row for the precise value (Ki, EC50…)
Subjective signature
Hover over an axis to read its definition.
- Calm3
- Clarity10
- Sleep3
- Appetite2
- High3
Editorial estimate, not clinical.
Pharmacology
MK-9470 is the reference tracer for visualising the CB1 receptor in the human brain by positron emission tomography. Described in 2007 by Burns and colleagues, it is a selective inverse agonist of very high affinity, with a median inhibitory concentration of 0.7 nanomolar at the human receptor, labelled with fluorine 18. Its validation followed the complete approach expected of a radioligand. Autoradiography on macaque brain showed a distribution consistent with the established map of the receptor, dense in the cortex, the cerebellum, the basal ganglia, the substantia nigra and the hippocampus. Imaging in animals confirmed that distribution in vivo, with a ratio of total to non-specific binding of four to five in the putamen, a blockade of the signal by pretreatment with a potent inverse agonist and a displacement of already bound tracer, two criteria that establish specificity. In humans, the behaviour of the tracer proved very close to that observed in monkeys, with a reproducibility between two successive examinations of 7 per cent. The final demonstration concerned the expected use: oral administration of an inverse agonist under development produced a reduction of the signal proportional to the dose, that is a direct measure of receptor occupancy by the drug. The tracer subsequently served questions of human neurobiology, notably the demonstration of an increase in receptor availability with age, differing by sex, and the study of the receptor in chronic cannabis users.
Key sources.
- Burns et coll. 2007 : le [18F]MK-9470, traceur TEP du récepteur CB1 pour l'imagerie cérébrale humainePMID 17535893
- Van Laere et coll. 2008 : augmentation de la liaison au CB1 avec l'âge chez l'humain, dépendante du sexePMID 18077184
- Ceccarini et coll. 2015 : mesure par [18F]MK-9470 de la disponibilité du CB1 chez les consommateurs chroniques de cannabisPMID 24373053
Origin (research tool)
An entirely chemical route, described here by class only. The molecule is an amide built around a propylamine skeleton linking a cyanophenyl to a phenyl bearing a fluoroethoxy chain, the whole being linked by the amide function to a methylpyridyloxy motif. Isotopic labelling consists in introducing fluorine 18 onto the ethoxy chain, an operation carried out in one step in the automated versions of the preparation.
Legal framework
France
A substance listed neither among narcotics nor among psychotropics. In its radiolabelled form it falls under the regulation of radiopharmaceuticals and the rules of radiation protection, and its use is confined to imaging centres holding the corresponding authorisations, within a research framework.
European Union
Not controlled as a narcotic. The compound holds no marketing authorisation as a radiopharmaceutical; its use falls within clinical research and hospital preparations governed by the regulation applicable to radiopharmaceuticals.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Structural classification
- Class
- ECS modulator (research)
- Origin
- A wholly synthetic compound. Its useful form is labelled with fluorine 18, a short-lived radionuclide produced in a cyclotron, which requires preparation within the hour preceding the examination and rules out any storage. It has no natural occurrence.
- Status
- Unscheduled
References
- 1.Burns et coll. 2007 : le [18F]MK-9470, traceur TEP du récepteur CB1 pour l'imagerie cérébrale humainePMID 17535893
- 2.Van Laere et coll. 2008 : augmentation de la liaison au CB1 avec l'âge chez l'humain, dépendante du sexePMID 18077184
- 3.Ceccarini et coll. 2015 : mesure par [18F]MK-9470 de la disponibilité du CB1 chez les consommateurs chroniques de cannabisPMID 24373053
Structured data
- InChIKey
- XIYPJXKEMLKFMD-HFZDXXHNSA-N
- SMILES
- CC1=CN=C(C=C1)OC(C)(C)C(=O)N[C@@H](C)[C@@H](CC2=CC=C(C=C2)OCCF)C3=CC=CC(=C3)C#N
- Formula
- C29H32FN3O3
- Molar mass
- 489.60 g·mol⁻¹
- CAS
- 947371-30-4
- PubChem CID
- 11488705
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.